FOCUS ON Molecular Pathology: NTRK fusions

To



NTRK inhibitors have been approved in many countries for treatment of solid tumours with gene fusions involving *NTRK1, NTRK2* or *NTRK3.* Over 50 partner genes have been identified with many different breakpoints which can make detection of these fusions challenging.
NTRK inhibitors are the first, histology agnostic treatment for solid tumours to be approved in Europe in September 2019 and have been approved for reimbursement by NICE in April 2020 (England).

In 2020, GenQA launched an EQA for pan-cancer testing of solid tumours for NTRK fusions:

- Participants were provided with formalin-fixed paraffin embedded tissues sections and expected to perform extraction of nucleic acid and test according to their usual laboratory protocols
- This EQA focused on laboratories performing next generation sequencing and assessment was for genotyping only.

GenQA also provides EQA for the following tumour types and pathology tests:

- Lung cancer: **tumour testing** and **cfDNA testing**
- Bone & soft tissue: **Sarcoma** and **GIST**
- **Colorectal cancer** and **microsatellite instability (MSI)**
- **Central Nervous system (CNS) tumours**
- Skin cancer: **melanoma**
- **Ovarian cancer, prostate cancer, pancreatic cancer: BRCA testing (**germline and somatic)
- **Breast cancer:** *PIK3CA* testing and gene expression profiling
- **Thyroid and Renal cancer**

Molecular Pathology webinar
Thursday 29th October 2020 1pm

- **Overview of GenQA Molecular Pathology EQA**
- **The challenges of testing for NTRK fusions**
- **Best practice for NTRK testing and reporting**
- **Results from the first NTRK *pilot EQA***
- **LIVE question and answer session**

Register for the free webinar and live Q&A session, at https://attendee.gotowebinar.com/register/1847800069307764752 by **28th October 2020.**
If you wish to submit a question for the Q&A session then please email info@genqa.org
Registered participants will have priority access to the webinar for one month (if you are unable to join us on the 29th October).

We look forward to receiving your questions!

FOCUS ON next month:

Molecular Newborn Screening